However, these medications have been reported to increase the frequency of some adverse reactions (eg, gastrointestinal intolerance, including abdominal discomfort, nausea, vomiting, and diarrhea) (6, 10), and adherence challenges of injectable therapies are further exacerbated in young patients (as seen in adherence to insulin therapy) (6, 11), highlighting the urgent need for novel oral treatment options with fewer adverse effects for pediatric patients with T2D. This evidence concerns the gene INS and type 2 diabetes mellitus.